Adipose Tissue‐Targeted Delivery of Rosiglitazone With Iron Oxide Nanoparticles Ameliorates Insulin Resistance in Male Mice
Obesity · 2026-05 · 34 (5) · 1068-1080
DOI: 10.1002/oby.70182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, online erschienen am 31.03.2026. Verfasst von Jakob E Ostberg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Sciences, University of Northern British Columbia, Prince George, British Columbia, Canada. Hauptthemen laut MEDLINE: Rosiglitazone, Insulin Resistance, Magnetic Iron Oxide Nanoparticles, Obesity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: New Frontiers in Research Fund - Expoloration, Tier 2 Canada Research Chair - Integrative Physiology of Diabetes, CIHR.
Abstract (Originalsprache)
Objective
This study aimed to assess iron oxide magnetic nanoparticles (MNPs) for adipose tissue‐targeted therapeutics to restore adipose tissue function and insulin sensitivity in obesity.
Methods
The insulin‐sensitizing effects of rosiglitazone and known adverse effects were leveraged for this proof‐of‐concept assessment of adipose tissue drug targeting. Rosiglitazone was adsorbed to alendronic acid‐coated MNPs (rosiMNPs) and a biocompatible magnet implanted in the right inguinal white adipose tissue (ingWAT) of obese, insulin resistant male mice. Following rosiMNP treatment (1.5 mg/kg/day, 18 days), insulin sensitivity and adipose tissue health were assessed.
Results
RosiMNPs restored insulin sensitivity as well as systemic rosiglitazone (1.5 mg/kg/day, 18 days), with a shift in adipocyte size compatible with PPARγ‐induced adipocyte hyperplasia and no increase in circulating adiponectin. PPARγ target genes were induced in ingWAT with rosiMNPs or systemic rosiglitazone, but only in liver and gonadal WAT of systemically treated mice. Additionally, iron accumulation was shown in the right, targeted ingWAT depot, but not in the left, untargeted ingWAT, kidney, or liver, suggesting targeting was achieved. Unfortunately, the dose and duration of systemic treatment were ineffective at inducing changes in kidney.
Conclusions
Results demonstrate the potential benefits of adipose tissue‐targeted therapeutics to improve adipose tissue function to restore insulin sensitivity to prevent the metabolic complications of obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Sciences, University of Northern British Columbia, Prince George, British Columbia, Canada.
- Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
ORCID-Profile: Parleen K Pandher, Urs O Häfeli, Sarah L Gray
Förderung
- New Frontiers in Research Fund - Expoloration
- Tier 2 Canada Research Chair - Integrative Physiology of Diabetes
- CIHR
- Natural Sciences and Engineering Research Council of Canada
- University of Northern British Columbia
- Canadian Institutes of Health Research
Zitieren
APA
Ostberg, J. E., Ahmed, Z., Saatchi, K., Pandher, P. K., Rahim, Y., Häfeli, U. O., & Gray, S. L. (2026). Adipose Tissue‐Targeted Delivery of Rosiglitazone With Iron Oxide Nanoparticles Ameliorates Insulin Resistance in Male Mice. Obesity, 34(5), 1068-1080. https://doi.org/10.1002/oby.70182
Vancouver
Ostberg JE, Ahmed Z, Saatchi K, Pandher PK, Rahim Y, Häfeli UO, et al. Adipose Tissue‐Targeted Delivery of Rosiglitazone With Iron Oxide Nanoparticles Ameliorates Insulin Resistance in Male Mice. Obesity. 2026;34(5):1068-1080. doi:10.1002/oby.70182
BibTeX
@article{Ostberg2026,
author = {Ostberg, Jakob E and Ahmed, Zeeshan and Saatchi, Katayoun and Pandher, Parleen K and Rahim, Yamna and Häfeli, Urs O and Gray, Sarah L},
title = {Adipose Tissue‐Targeted Delivery of Rosiglitazone With Iron Oxide Nanoparticles Ameliorates Insulin Resistance in Male Mice},
journal = {Obesity},
year = {2026},
volume = {34},
number = {5},
pages = {1068--1080},
doi = {10.1002/oby.70182}
}
EUVIMED